Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers in this study are comparing two different treatments for Hodgkin lymphoma (HL). The people in this study have early-stage (stage 1 or 2) HL that has not yet been treated.
Researchers want to find the best dose of BMS-986504 to use safely in people with lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their tumors are missing the MTAP gene.
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
Researchers want to find the best doses of MOMA-313 alone and with olaparib in people with cancer. The people in this study have advanced castration-resistant prostate cancer (CRPC) or pancreatic cancer. CRPC is prostate cancer that has spread and keeps growing even in the absence of hormones. Their cancers also have a genetic change called HR deficiency.
Researchers are doing this study to see if the combination of epcoritamab, zanubrutinib, and rituximab works well against lymphoma. The people in this study have follicular lymphoma that has come back or keeps growing after treatment.
Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Researchers want to find the best dose of avutometinib to treat children and young adults with advanced solid tumors. The people in this study have cancers that have spread or come back after treatment. In addition, their cancers have a mutation (change or variant) in a protein family called MAPK. These proteins tell cancer cells to grow.
This study aims to obtain a better understanding of the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. Together these diseases are referred to as "lymphoproliferative disorders."
Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.
Researchers want to see if removing only 1 lymph node with cancer prevents melanoma from coming back in that area. The people in this study have melanoma that spread to just 1 lymph node.
